What is TECLens?
TECLens is at the forefront of ophthalmic innovation, specializing in the development of a non-invasive cornea cross-linking procedure. The company's core technology, the CXLens, utilizes a single-use disposable contact lens paired with a sophisticated control system to deliver patterned ultraviolet light and real-time ultrasound feedback. This approach is designed to treat both eyes simultaneously, offering a potentially safer and more permanent alternative to traditional refractive surgeries like LASIK, as well as conventional corrective eyewear.
By targeting conditions ranging from keratoconus to low-order myopia and eventually presbyopia, TECLens is addressing a significant global market need. Its clinical-stage status indicates a transition from foundational research to rigorous validation, positioning the firm as a disruptive force in the medical device sector.
How much funding has TECLens raised?
TECLens has raised a total of $15.7M across 3 funding rounds:
Private Equity
$1.2M
Series A
$9.3M
Debt
$5.2M
Private Equity (2017): $1.2M, investors not publicly disclosed
Series A (2025): $9.3M led by Sunmed Capital, Rimonci Capital, Yonjin Venture, and Johnson & Johnson Innovation
Debt (2026): $5.2M, investors not publicly disclosed
Key Investors in TECLens
Johnson & Johnson Innovation
A global leader in healthcare innovation that partners with early-stage businesses to develop transformational medical devices and pharmaceutical solutions.
Rimonci Capital
A specialized investment firm focused on China-Israel cross-border opportunities, with a deep emphasis on medical devices and high-potential technology transfer.
Yonjin Venture
A venture capital entity dedicated to identifying and supporting innovative technologies within the therapeutics, diagnostics, and medical device sectors.
What's next for TECLens?
With the recent influx of capital, TECLens is expected to prioritize the expansion of its clinical trial infrastructure and the optimization of its CXLens manufacturing processes. The strategic focus will likely shift toward securing regulatory milestones and preparing for commercialization in key global markets. As the company moves deeper into its clinical-stage lifecycle, the integration of its proprietary technology into standard ophthalmic practice will be the primary driver of long-term value creation.
The backing from a diverse group of institutional investors suggests a robust roadmap for future growth, with potential for further strategic partnerships or M&A activity as the technology matures. TECLens remains committed to its mission of providing a simple, effective, and permanent solution for millions of individuals suffering from vision impairment.
